Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-020416
Filing Date
2025-02-14
Accepted
2025-02-14 07:54:51
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6990
  Complete submission text file 0000950170-25-020416.txt   8778
Mailing Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036
Business Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036 929-999-4055
Dianthus Therapeutics, Inc. /DE/ (Subject) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90538 | Film No.: 25623270
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 CLARENDON STREET BOSTON MA 02116
Business Address 200 CLARENDON STREET BOSTON MA 02116 6175162000
BCLS Fund III Investments, LP (Filed by) CIK: 0001952107 (see all company filings)

EIN.: 873064173 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A